Video

Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse

Through Medication Therapy Management, a pharmacist will be able to recognize indications of potential opioid abuse, explained Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare.

Through Medication Therapy Management, a pharmacist will be able to recognize indications of potential opioid abuse, explained Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare.

Transcript

How can Medication Therapy Management be used to address opioid misuse?

In the course of an MTM [Medication Therapy Management] consultation or a comprehensive medication review, a pharmacist will review all of the medications the patient is taking, and that will also include, in better MTM programs, over-the-counter medications and vitamin supplements. In the course of looking at all of the medications, which will include opioids, a pharmacist will be able to see trends, with respect to the opioids, such as multiple refills, different prescribers writing prescriptions for opioids, and filling prescriptions across state lines. These are all indications of potential abuse.

Tabula Rasa HealthCare has announced their Optimized Opioid Solution. How will this solution identify and prevent opioid misuse?

TRHC looks at medications in the MTM context very differently than other MTM companies. Rather than looking at single drug to drug interactions, Tabula Rasa looks at accumulative, simultaneous multi-drug interactions. So, we’re looking at the entire cocktail of medications. What this means with respect to opioids is that a patient who’s taking opioids and other medications, there may be interactions between those other medications and the opioid that can lead to serious problems.

The opioid could provide more analgesic impact to the body than the prescriber would expect, or it might provide less, which also causes serious problems. So, by identifying the impact of the other medications that a patient is taking along with the opioid, we can get a head start on risk associated with unintentional misuse of opioids that lead to potential abuse.

Related Videos
Richard J. Nowak, MD, MS, Yale School of Medicine
Drs Lillian L. Siu and Matthew G. Vander Heiden
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo